William Blair Brokers Boost Earnings Estimates for DVAX

Dynavax Technologies Co. (NASDAQ:DVAX) – Stock analysts at William Blair raised their Q4 2024 earnings estimates for shares of Dynavax Technologies in a report issued on Monday, January 13th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $0.02 per share for the quarter, up from their previous forecast of $0.01. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. William Blair also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.48 EPS.

Several other brokerages have also recently issued reports on DVAX. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright upped their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday.

Dynavax Technologies Stock Up 0.5 %

DVAX stock opened at $12.45 on Thursday. The company has a market cap of $1.64 billion, a P/E ratio of 95.78 and a beta of 1.34. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.30. The stock’s 50 day simple moving average is $12.76 and its 200 day simple moving average is $11.67. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in Dynavax Technologies during the 2nd quarter valued at approximately $17,615,000. Great Point Partners LLC grew its stake in Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Dynavax Technologies during the third quarter valued at about $8,291,000. PDT Partners LLC acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at $3,967,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Dynavax Technologies in the 2nd quarter worth approximately $3,144,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.